Modifying Antiretroviral Therapy in Virologically Suppressed HIV-Infected Patients
Summary
- Studies examining the efficacy of switching NNRTIs in virologically suppressed patients because of toxicity found a majority of patients safely maintained virologic suppression[Gulick 2006; Schouten 2010; Parienti 2007]
- Switch to emtricitabine/rilpivirine/tenofovir AF from emtricitabine/rilpivirine/tenofovir DF or efavirenz/emtricitabine/tenofovir DF noninferior with improvements in bone and renal safety[Orkin 2017] Switching from Other NNRTIs to Doravirine
- A total of 24% of participants in the DRIVE-SHIFT trial,[Johnson 2019] which evaluated a switch to doravirine/lamivudine/tenofovir DF in virologically suppressed patients on stable ART for ≥ 6 months with no previous virologic failure or resistance to doravirine if they were on NNRTI-based regimens before the switch
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content